Cardiff Oncology Inc (CRDF)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

11055 FLINTKOTE AVENUE SAN DIEGO, CA 92121

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to overcome resistance, improve response to treatment and increase overall survival. The company is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. Cardiff has three clinical programs that have demonstrated the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). A new Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is planned for initiation in the first half of 2021.

Data as of 2021-07-25 16:53:31 -0400
Market Cap199.402 Million Shares Outstanding37.552 Million Avg 30-day Volume745.975 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.24 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.74476 52-week High/Low25.5 / 4.29 Next Earnings Date2021-08-10 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from CRDF instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 3 -33.33% 1 (0.06%) 2 (0.12%) -50.0%
Funds Holding: 74 84 -11.9% 22 (1.29%) 28 (1.63%) -21.43%
13F shares: 24.079 Million 26.637 Million -9.6% 10.623 Million 12.545 Million -15.32%
% Ownership 64.1227 75.4059 -14.96% 28.2896 35.5139 -20.34%
New Positions: 18 35 -48.57% 3 15 -80.0%
Increased Positions 32 17 88.24% 12 5 140.0%
Closed Positions 28 20 40.0% 9 10 -10.0%
Reduced Positions 13 20 -35.0% 4 6 -33.33%
Total Calls 339.902 Thousand 463.738 Thousand -26.7% 124.575 Thousand 103.222 Thousand 20.69%
Total Puts 811.934 Thousand 752.247 Thousand 7.93% 480.118 Thousand 484.419 Thousand -0.89%
PUT/CALL Ratio 2.39 1.62 47.53% 3.85 4.69 -17.91%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Cardiff Oncology Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CRDF (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRDF BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LEVINE JAMES E. CHIEF FINANCIAL OFFICER

  • Officer
 390,000 2021-07-12 2

RUFFNER KATHERINE L CHIEF MEDICAL OFFICER

  • Officer
 200,000 2021-07-12 2

BRANCACCIO JOHN P

  • Director
 98,517 2021-06-10 2

JACOB GARY S

  • FORMER DIRECTOR
 608,848 2021-06-10 2

ADAMS THOMAS PHD

  • FORMER DIRECTOR
 3,345,090 2021-06-10 1

MARKIN RODNEY S

  • Director
 97,827 2021-06-10 2

ERLANDER MARK CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 815,272 2021-06-10 3

PACE GARY W

  • Director
 62,774 2021-06-10 5

ARMITAGE JAMES O

  • Director
 62,774 2021-06-10 2

WHITE LALE

  • Director
 62,774 2021-06-10 1

KELEMEN VICKI EXEC. VP AND COO

  • Officer
 402,768 2021-06-10 4

MOHINDRU MANI

  • Director
 0 2021-06-10 2

TANNENBAUM RENEE P

  • Director
 44,001 2021-06-10 2

RA CAPITAL MANAGEMENT, L.P.

KOLCHINSKY PETER

SHAH RAJEEV M.

  • 10% Owner
 3,290,000 2020-09-30 1

COUNTOURIOTIS ATHENA

  • Director
 0 2019-06-20 0

TENNANT STANLEY

  • Director
 28,839 2018-06-08 0

WELCH WILLIAM J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 842,645 2018-01-30 0

BILLINGS PAUL

  • Director
 0 2018-01-23 0

BRIDGER MANAGEMENT, LLC

MIGNONE ROBERTO

  • 10% Owner
  • FORMER 10% OWNER
No longer subject to file 2016-11-11 0

ZANIBONI STEVE FORMER CFO

  • Officer
 96,968 2016-04-21 0

SCHUH ANTONIUS CEO

  • Officer
  • Director
 0 2016-01-04 0

POSARD MATTHEW L. CHIEF COMMERCIAL OFFICER

  • Officer
 0 2016-01-04 0

FELDBAUM CARL B

  • Director
 0 2015-03-17 0

CERRONE GABRIEL

  • FORMER DIRECTOR
 0 2013-07-26 0

MCGUIGAN CHRISTOPHER

  • Director
 0 2013-02-14 0

HUNTER ROBERT MERRILL

  • 10% Owner
 5,065,004 2012-04-13 0

SHEINERMAN KIRA

  • Director
 909,090 2008-06-12 0

POLIAKOFF ABBA DAVID

  • Director
 0 2008-01-03 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

RUFFNER KATHERINE L - Officer CHIEF MEDICAL OFFICER

2021-07-14 16:00:35 -0400 2021-07-12 A 200,000 a 200,000 direct

LEVINE JAMES E. - Officer CHIEF FINANCIAL OFFICER

2021-07-12 16:16:15 -0400 2021-07-12 A 390,000 a 390,000 direct

WHITE LALE - Director

2021-06-14 16:14:14 -0400 2021-06-10 A 22,000 a 62,774 direct

JACOB GARY S FORMER DIRECTOR

2021-06-15 10:06:43 -0400 2021-06-10 J 44,734 a 76,106 direct

JACOB GARY S FORMER DIRECTOR

2021-06-15 10:06:43 -0400 2021-06-10 J 223 a 76,106 direct

JACOB GARY S FORMER DIRECTOR

2021-06-15 10:06:43 -0400 2021-06-10 J 293 a 76,106 direct

ADAMS THOMAS PHD FORMER DIRECTOR

2021-06-14 16:10:39 -0400 2021-06-10 J 173,145 a 477,870 direct

ADAMS THOMAS PHD FORMER DIRECTOR

2021-06-14 16:10:39 -0400 2021-06-10 J 530 a 477,870 direct

ADAMS THOMAS PHD FORMER DIRECTOR

2021-06-14 16:10:39 -0400 2021-06-10 J 272 a 477,870 direct

KELEMEN VICKI - Officer EXEC. VP AND COO

2021-06-14 16:12:09 -0400 2021-06-10 A 200,928 a 402,768 direct

PACE GARY W - Director

2021-06-14 16:13:09 -0400 2021-06-10 A 22,000 a 62,774 direct

JACOB GARY S FORMER DIRECTOR

2021-06-15 10:06:43 -0400 2021-06-10 J 755 a 76,106 direct

JACOB GARY S FORMER DIRECTOR

2021-06-15 10:06:43 -0400 2021-06-10 J 223 a 76,106 direct

JACOB GARY S FORMER DIRECTOR

2021-06-15 10:06:43 -0400 2021-06-10 J 28,858 a 76,106 direct

ADAMS THOMAS PHD FORMER DIRECTOR

2021-06-14 16:10:39 -0400 2021-06-10 J 298,320 a 477,870 direct

ADAMS THOMAS PHD FORMER DIRECTOR

2021-06-14 16:10:39 -0400 2021-06-10 J 223 a 477,870 direct

ARMITAGE JAMES O - Director

2021-06-14 16:11:06 -0400 2021-06-10 A 22,000 a 62,774 direct

MARKIN RODNEY S - Director

2021-06-14 16:12:31 -0400 2021-06-10 A 22,000 a 97,827 direct

TANNENBAUM RENEE P - Director

2021-06-14 16:13:36 -0400 2021-06-10 A 44,001 a 44,001 direct

JACOB GARY S FORMER DIRECTOR

2021-06-15 10:06:43 -0400 2021-06-10 J 530 a 76,106 direct

JACOB GARY S FORMER DIRECTOR

2021-06-15 10:06:43 -0400 2021-06-10 J 218 a 76,106 direct

BRANCACCIO JOHN P - Director

2021-06-14 16:11:30 -0400 2021-06-10 A 22,000 a 98,517 direct

ADAMS THOMAS PHD FORMER DIRECTOR

2021-06-14 16:10:39 -0400 2021-06-10 J 755 a 477,870 direct

ADAMS THOMAS PHD FORMER DIRECTOR

2021-06-14 16:10:39 -0400 2021-06-10 J 223 a 477,870 direct

ERLANDER MARK - Director - Officer CHIEF EXECUTIVE OFFICER

2021-06-14 16:11:48 -0400 2021-06-10 A 435,072 a 815,272 direct

MOHINDRU MANI - Director

2021-06-14 16:12:51 -0400 2021-06-10 A 44,001 a 44,001 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CARDIFF ONCOLOGY INC CRDF 2021-08-02 19:45:03 UTC -2.0096 2.0696 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 19:15:03 UTC -2.0096 2.0696 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 18:45:03 UTC -2.0096 2.0696 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 18:15:03 UTC -2.0096 2.0696 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 17:45:03 UTC -2.0096 2.0696 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 17:15:03 UTC -2.0096 2.0696 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 16:45:03 UTC -1.9992 2.0792 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 16:15:03 UTC -1.9992 2.0792 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 15:45:03 UTC -1.9992 2.0792 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 15:15:03 UTC -1.9992 2.0792 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 14:45:03 UTC -2.0028 2.0828 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 14:15:03 UTC -2.0028 2.0828 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 13:45:03 UTC -2.0028 2.0828 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 13:15:04 UTC -2.0028 2.0828 750000
CARDIFF ONCOLOGY INC CRDF 2021-08-02 12:45:03 UTC -2.0028 2.0828 750000
CARDIFF ONCOLOGY INC CRDF 2021-07-30 22:15:02 UTC -2.0028 2.0828 650000
CARDIFF ONCOLOGY INC CRDF 2021-07-30 21:45:03 UTC -2.0028 2.0828 650000
CARDIFF ONCOLOGY INC CRDF 2021-07-30 21:15:03 UTC -2.0028 2.0828 650000
CARDIFF ONCOLOGY INC CRDF 2021-07-30 20:45:02 UTC -2.0028 2.0828 650000
CARDIFF ONCOLOGY INC CRDF 2021-07-30 20:15:02 UTC -2.0028 2.0828 650000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
RBB Fund, Inc.- Boston Partners Long/Short Equity Fund CRDF -6287.0 shares, $-52810.8 2021-05-31 N-PORT

Elevate your investments